Cytokinetics CYTK CH — Operating Lease Liability
Discontinued — last reported Q4 '25
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Cytokinetics in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiability.
The official record: Cytokinetics’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →
Ask your AI about Cytokinetics's ch — operating lease liability.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Cytokinetics's CH — operating lease liability?
- Cytokinetics (CYTK) reported CH — operating lease liability of $2.6M in Q4 2025.
- What does CH — operating lease liability mean?
- The total financial obligation for future lease payments related to the CH segment.
- How do you interpret CH — operating lease liability?
- An increase reflects higher future financial commitments, potentially increasing leverage, while a decrease indicates the paydown or expiration of lease obligations.
- How does CH — operating lease liability compare across companies?
- Biotech companies with significant R&D facilities often carry substantial lease liabilities proportional to their laboratory and office space requirements.